Description of the medicine: Mercapturin (Mercaptopurinum)
MERCAPTOPURIN (Mercaptopurinum). 6-mercaptopurine (monohydrate).
Synonyms: Leukerin, Leukerin, Leupurin, Purinetol, Ismipur, Leukerin, Leupurin, Mercalenein, Mercaptopurine, Mercapurin, Mycaptine, Oncomercaptopurina, Purinethol.
Yellow crystalline powder. It is practically insoluble in water and alcohol, soluble in hot water, in alkali solutions.
Mercaptopurine is an antimetabolite of purines. By structure, 6-mercaptopurine is close to adenine (6-aminopurin), hypoxanthine (6-hydroxypurin), guanine (2-amino-6-hydroxypurin).
Being a structural analogue - an antimetabolite of these compounds that are part of nucleic acids (DNA, RNA), mercaptopurine disrupts the biosynthesis of nucleotides, inhibits the growth of proliferating tissues and exerts a cytotoxic effect.
Mercapturin is used in the treatment of acute (subacute) leukemia, as well as in exacerbations of chronic myelogenous leukemia, which proceeds as an acute leukemia. It is also used in uterine chorionepithelioma (usually in combination with methotrexate) and in the treatment of reticulosis.
The drug can be used in patients with acute leukemia in cases of developed resistance to anti-folic drugs - methotrexate,
Assign inside 2, 0, 2, 5 mg / kg in one or two doses. If the therapeutic effect does not occur, the daily dose is increased to 5 mg / kg (no more).
Mercapturin, like other cytotoxic drugs, has immunosuppressive activity and is used in some cases (at doses of 50 - 150 mg per day) for the treatment of autoimmune diseases: rheumatoid arthritis, chronic hepatitis, lupus nephritis, etc. (see Immunosuppressive drugs).
Mercapturin is also used to treat psoriasis. Assign to adults 0.05 g 2 to 3 times a day in 10-day cycles at 3-day intervals. A total of 3 to 4 cycles are carried out. Treatment usually gives a temporary effect.
When using mercaptopurine, side effects can be observed: general weakness, lesions of the oral mucosa, dyspeptic symptoms with vomiting and diarrhea. Like other cytostatics, mercaptopurine can cause leukemia thrombocytopenia.
Treatment with mercaptopurine should be carried out under close clinical and hematological monitoring.
With pronounced phenomena of inhibition of hematopoiesis, the drug is canceled and hemostimulating therapy is prescribed. During and after treatment (within 2 weeks) at least 2 times a week, peripheral blood and bone marrow hematopoiesis are monitored.
Monitoring of liver and kidney function is required.
Mercaptopurin is contraindicated in case of leukopenia (white blood cells less than 3 x 10 / l of blood), thrombocytopenia (platelets less than 100 x 109 / l), with diseases of the liver, kidneys, and pregnancy.
Release form: tablets on 0,05 g.
Storage; List A. In well-closed containers.